Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

53.50
BATS BZX Real-Time Price
As of 2:37pm ET
 +0.02 / +0.04%
Today’s Change
43.57
Today|||52-Week Range
57.42
+17.30%
Year-to-Date
Regeneron's Knock-out Quarter Could Be Just The Beginning
1:04pm / MotleyFool.com
Sanofi & Regeneron Enter Immuno-Oncology Collaboration - Analyst Blog
Jul 29 / Zacks.com
Regeneron Beats on Q2 Earnings, Eylea 2015 View Upped - Analyst Blog
10:47am / Zacks.com
MannKind Relies on 'Death Spiral' Financing to Help Settle Looming Debt
Jul 29 / TheStreet.com
Sanofi Tops Q2 Earnings, Revenues Grow Y/Y, Maintains View - Analyst Blog
Jul 31 / Zacks.com
Struggling Sanofi Sends Cancer SOS to Regeneron and Another Vanity Biotech IPO Launch...
Jul 28 / TheStreet.com
VIVUS (VVUS) Q2 Loss Narrower, Restructuring Announced - Analyst Blog
Jul 31 / Zacks.com
Regeneron Pharmaceuticals and Sanofi Grab a Blockbuster FDA Approval
Jul 27 / MotleyFool.com
MannKind Triples Production Capacity for Afrezza
Jul 31 / Benzinga
Amgen's Repatha Gains EU Nod; First PCSK9 Drug Approved - Analyst Blog
Jul 22 / Zacks.com
Sanofi (SNY) Earnings Report: Q2 2015 Conference Call Transcript
Jul 30 / TheStreet.com
Actelion Misses on Q2 Earnings, Revenues Beat Expectations - Analyst Blog
Jul 22 / Zacks.com
3 Drugs Stocks Pushing Industry Growth
Jul 30 / TheStreet.com
Abbott Laboratories (ABT) Beats on Q2 Earnings, Keeps View - Analyst Blog
Jul 22 / Zacks.com
Why MannKind Corp. Stock Briefly Dropped Today
Jul 30 / MotleyFool.com
Pharma Stock Outlook - July 2015 - Zacks Analyst Interviews
Jul 21 / Zacks.com
MannKind Afrezza Sales Underwhelming Again, Sanofi Reports
Jul 30 / TheStreet.com
Pharma Stock Outlook - July 2015 - Industry Outlook
Jul 21 / Zacks.com
3 Stocks Pushing The Drugs Industry Lower
Jul 29 / TheStreet.com